|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayPress Release: Surveyed U.S. Neurologists Would be Willing to Accept a Novel Primary-Progressive Multiple Sclerosis Therapy with Safety Risk if Proven Effective on Disability Progression
BURLINGTON, Mass., April 8, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive multiple sclerosis (PP-MS), surveyed U.S. neurologists would be willing to accept a certain level of risk for a therapy with proven efficacy on disability progression, likely owing to the absence of approved therapies for this indication.
Read more » Labels: Gilenya, Primary-Progressive PPMS |